Clinical Trial Update: Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating the efficacy and resistance mechanisms of an investigational product (IP) in non-small cell lung cancer with leptomen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IP

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING